DrugIn clinical trials
Лорундростат
lorundrostat
Таблетка раз в день, снижающая выработку альдостерона; фаза 3 Launch-HTN (NCT06153693) у взрослых с неконтролируемой гипертонией на 2–5 препаратах. На рассмотрении FDA, целевая дата 22.12.2026. Не одобрен.
Also in the catalogue
- Feifel D, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression. JAMA, 2026Publication
- Vacheron CH, et al. Influence of Preoperative Virtual Reality on Preoperative State Anxiety in the Ambulatory Setting: The AMBLUMEEN RCT. Anesth Analg, 2026Publication
- Yang Y, et al. SGLT2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: Meta-Analysis of RCTs. JAMA, 2026Publication
- Мебуфотенин (5-MeO-DMT, BPL-003)Drug
- UpacicalcetDrug
- DivarasibDrug
Scales
Identifiers
- INN
- lorundrostat
Details
- Status
- In clinical trials
- Class
- ингибитор альдостеронсинтазы
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.